These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 12687416)

  • 1. In vitro antibacterial activity and pharmacodynamics of new quinolones.
    Dalhoff A; Schmitz FJ
    Eur J Clin Microbiol Infect Dis; 2003 Apr; 22(4):203-21. PubMed ID: 12687416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
    Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
    Blondeau JM; Laskowski R; Bjarnason J; Stewart C
    Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
    Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.
    Almer LS; Hoffrage JB; Keller EL; Flamm RK; Shortridge VD
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2771-7. PubMed ID: 15215148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility of 4903 bacterial isolates to gemifloxacin--an advanced fluoroquinolone.
    Blondeau JM; Hansen G; Metzler KL; Borsos S; Irvine LB; Blanco L
    Int J Antimicrob Agents; 2003 Aug; 22(2):147-54. PubMed ID: 12927955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro activity of gemifloxacin against gram-positive and gram-negative clinical isolates in Argentina.
    Lopez H; Stepanik D; Vilches V; Scarano S; Sarachian B; Mikaelian G; Finlay J; Sucari A
    Diagn Microbiol Infect Dis; 2001 Aug; 40(4):187-92. PubMed ID: 11576792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of gemifloxacin.
    King A; May J; French G; Phillips I
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():1-12. PubMed ID: 10824026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.
    Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
    Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):814-9. PubMed ID: 11783700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S; Ianniello F; Leone S; Esposito S
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'.
    Blondeau JM
    J Antimicrob Chemother; 1999 May; 43 Suppl B():1-11. PubMed ID: 10382869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antibacterial activity of quinolones against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].
    Nakamura T; Shimizu C; Hirakawa K; Inui S; Okuda K; Nakata C; Fujimoto H; Okura H; Uemura Y; Takahashi H
    Jpn J Antibiot; 2009 Jun; 62(3):194-202. PubMed ID: 19882980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.
    Zhanel GG; Fontaine S; Adam H; Schurek K; Mayer M; Noreddin AM; Gin AS; Rubinstein E; Hoban DJ
    Treat Respir Med; 2006; 5(6):437-65. PubMed ID: 17154673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic studies of trovafloxacin and grepafloxacin in vitro against Gram-positive and Gram-negative bacteria.
    Odenholt I; Cars T; Lowdin E
    J Antimicrob Chemother; 2000 Jul; 46(1):35-43. PubMed ID: 10882686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone.
    Hoshino K; Inoue K; Murakami Y; Kurosaka Y; Namba K; Kashimoto Y; Uoyama S; Okumura R; Higuchi S; Otani T
    Antimicrob Agents Chemother; 2008 Jan; 52(1):65-76. PubMed ID: 17938194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanded activity and utility of the new fluoroquinolones: a review.
    Blondeau JM
    Clin Ther; 1999 Jan; 21(1):3-40; discussion 1-2. PubMed ID: 10090423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinolone activity against anaerobes.
    Appelbaum PC
    Drugs; 1999; 58 Suppl 2():60-4. PubMed ID: 10553708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of gemifloxacin against contemporary clinical bacterial isolates from eleven North American medical centers, and assessment of disk diffusion test interpretive criteria.
    Fuchs PC; Barry AL; Brown SD
    Diagn Microbiol Infect Dis; 2000 Dec; 38(4):243-53. PubMed ID: 11146251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gatifloxacin: a review of its use in the management of bacterial infections.
    Perry CM; Ormrod D; Hurst M; Onrust SV
    Drugs; 2002; 62(1):169-207. PubMed ID: 11790160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.